NCT00596804View on ClinicalTrials.gov

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Non-Hodgkin's LymphomaLymphoma, DiffuseLymphoma, Diffuse, Mixed Lymphocytic-Histiocytic
Interventions
DRUG

veltuzumab

once weekly intravenous dosing for 4 weeks

Trial Locations (3)

59037

Service Des Maladies Du Sang, Lille

69495

Centre hospitalier Lyon, Lyon

LE1 9HN

University of Leicester, Leicester

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00596804 - Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter